| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | November 24, 2023 |
| Accession Number: | 0001193125-23-280689 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/2/2022 | $9.00 | Buy | EF Hutton |
15-12G - Acer Therapeutics Inc. (0001069308) (Filer)
EFFECT - Acer Therapeutics Inc. (0001069308) (Filer)
EFFECT - Acer Therapeutics Inc. (0001069308) (Filer)
NEWTON, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced that Institutional Shareholder Services Inc. (ISS) and Glass, Lewis & Co. LLC (Glass Lewis) recommended that Acer shareholders vote "FOR" the proposed merger with Zevra Therapeutics, Inc. and the related proposals in the Company's proxy statement and prospectus for the special meeting of its shareholders to be held on November 8, 2023 at 11:00 a.m. Eastern Time. ISS and Glass Lewis are widely recognized a
NEW YORK, Sept. 02, 2023 (GLOBE NEWSWIRE) -- RPT Realty (NYSE:RPT) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of RPT to Kimco Realty for 0.6049 of a newly-issued Kimco Realty share for each share of RPT common stock owned. If you are a RPT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Hersha Hospitality Trust (NYSE:HT) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of HT to KSL Capit
Proposed acquisition of Acer for $15M in Zevra stock plus Contingent Value Rights (CVRs) and Zevra's purchase of Acer's secured debt in capital efficient structure Zevra to assume commercialization efforts of OLPRUVA™, recently approved for the treatment of urea cycle disorders (UCDs) FDA-approved commercial asset expected to increase and diversify Zevra's revenues OLPRUVA™ commercial operations provide Zevra scale and cost synergies to complement the potential launch of arimoclomol Adds EDSIVO™, a Phase 3 program for vascular Ehlers-Danlos Syndrome (vEDS), to Zevra's rare disease clinical pipeline Zevra to discuss details during conference call today, at 8:30 a.m. ET CELEBRATION, F
4 - Acer Therapeutics Inc. (0001069308) (Issuer)
4 - Acer Therapeutics Inc. (0001069308) (Issuer)
4 - Acer Therapeutics Inc. (0001069308) (Issuer)
Submission status for ACER THERAPEUTICS INC's drug OLPRUVA (ORIG-1) with active ingredient SODIUM PHENYLBUTYRATE has changed to 'Approval' on 12/22/2022. Application Category: NDA, Application Number: 214860, Application Classification: Type 5 - New Formulation or New Manufacturer
NEWTON, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2022 and provided an update on the Company's recent corporate developments. "Progress in Q1 2022 was marked by a transformative debt financing in March, with continued advancement toward potential commercial launch of ACER-001 for UCDs and further development of our other pipeline programs," said Chris Schelling, CEO and Founder of Acer. "Our advances
NEWTON, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on the Company's recent corporate developments. "We made significant progress this year in advancing our pipeline programs, including filing of our New Drug Application and key patent issuances for ACER-001, and receipt of two Investigational New Drug application clearances for our ACER-801 proof-of-con
NEWTON, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer. Dr. Quartel will oversee Acer's clinical development, medical affairs, regulatory and other scientific and medical functions. "We are pleased to welcome Dr. Quartel to our experienced leadership team," said Chris Schelling, CEO and Founder of Acer. "Dr. Quartel's proven track record of guiding the clinical development, approval and la
EF Hutton initiated coverage of Acer Therapeutics with a rating of Buy and set a new price target of $9.00
Proposed acquisition of Acer for $15M in Zevra stock plus Contingent Value Rights (CVRs) and Zevra's purchase of Acer's secured debt in capital efficient structure Zevra to assume commercialization efforts of OLPRUVA™, recently approved for the treatment of urea cycle disorders (UCDs) FDA-approved commercial asset expected to increase and diversify Zevra's revenues OLPRUVA™ commercial operations provide Zevra scale and cost synergies to complement the potential launch of arimoclomol Adds EDSIVO™, a Phase 3 program for vascular Ehlers-Danlos Syndrome (vEDS), to Zevra's rare disease clinical pipeline Zevra to discuss details during conference call today, at 8:30 a.m. ET CELEBRATION, F
Third Quarter 2022 Financial Results to be Announced in Early November DALLAS, Oct. 18, 2022 /PRNewswire/ -- SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an update on the progress and achievements of its borrower partners, including recent transactions and activities. "The second half of 2022 has been an active time for SWK. We have capitalized on our strong underlying business fundamentals to close several transactions, including two $25.0 million financings with Aziyo Biologics and MedMinder," stated Jody Staggs, President and Interim CEO of SWK.
Conference Call and Live Audio Webcast Scheduled for Monday, March 28, 2022, at 10:00 a.m. ET Corporate Highlights Reconstituted Board and appointed Wendy DiCicco, Robert K. Hatcher, and Laurie Dotter as independent directorsCompleted four transactions from December 2021 through March 2022, deploying $38.5 millionReceived a $10.7 million cash payment from B&D Dental to successfully resolve long-running non-accrual position. Loan carried at $8.3 millionIn December 2021, subsidiary Enteris received a $5.0 million milestone payment from Cara Therapeutics with SWK retaining $3.0 millionEnteris currently advancing six partner feasibility studiesFinance Receivables Segment Update As of December 31
SC 13D/A - Acer Therapeutics Inc. (0001069308) (Subject)
SC 13G/A - Acer Therapeutics Inc. (0001069308) (Subject)
SC 13D/A - Acer Therapeutics Inc. (0001069308) (Subject)